Anti-TNF treatment in Crohn's disease: toward tailored therapy?
Infliximab is a potent therapy for induction and maintenance of remission in Crohn's disease. Unfortunately, many patients lose response and/or develop allergic reactions caused by the chimeric antibody. By means of measuring the presence of antibodies against infliximab and the trough levels of the drug, it seems easier to predict whether patients will respond to intensified dose regimens or will rather benefit from a switch to alternative agents.
D'Haens
Geert
G
D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology*; D016503:Drug Delivery Systems; D004351:Drug Resistance / Q000276:immunology; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D011379:Prognosis; D018570:Risk Assessment; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab